Surgery for Lung Cancer: 356 Real Stories

356 stories match lung cancer and surgery. 177 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Lung squamous cell carcinoma spreading to bone and intestine

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 positive in almost all tumor cells

Metastatic Site: bone (left femur), intestine, abdomen

Despite chemotherapy, immunotherapy and radiation, the lung cancer progressed with intestinal and extensive abdominal metastases, cachexia and gastrointestinal bleeding. Palliative care was planned, but he chose discharge and received no further treatment.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA ALK-positive lung adenocarcinoma: pathologic complete response to lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: EML4-ALK fusion; ALK-positive; Napsin A-positive; cytokeratin-positive; TTF-1-positive

He remained disease-free 10 months after surgery while continuing planned adjuvant lorlatinib after neoadjuvant lorlatinib produced partial radiographic response and pathologic complete response.

PubMed Central
OutcomeCancer-Free / NED
Att, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD Anderson
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Stage IIIA EGFR-mutated lung adenocarcinoma: surgery after osimertinib

Patient Info: Anonymized, Male, 60s

Biomarkers: EGFR E746_A750 deletion; PD-L1 TPS 15%; TMB 5.01 Muts/Mb; TTF-1 3+; CK7 3+; Ki67 60%

As of July 2024, surveillance CT scans at 2, 6, and 12 months after surgery showed no recurrent malignancy while he continued adjuvant osimertinib.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3 lung cancer: complete response to chemo and immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Tumor markers were normal during mesorectal nodule workup; lung molecular biomarkers were not reported.

No radiologic NSCLC recurrence was detected during 16 months of follow-up after complete response to cisplatin/docetaxel chemoradiation plus 1 year of durvalumab; the suspicious mesorectal nodule proved to be a benign organized thrombus.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA ALK-rearranged NSCLC: pathologic complete response to neoadjuvant brigatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: ALK gene rearrangement; CEA 8.49 ng/mL

He remained disease-free during 13 months of follow-up after neoadjuvant brigatinib reduced Stage IIIA ALK-rearranged NSCLC and curative-intent surgery showed pathologic complete response.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Guillain-Barré syndrome after surgery for Stage II lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage II

No lung-cancer recurrence was seen at follow-up after complete resection. His postoperative Guillain-Barré syndrome resolved within 3 months after immunoglobulin treatment and rehabilitation.

PubMed Central
OutcomeCancer-Free / NED
Lenny, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Lenny's Survivor Story

Patient Info: Lenny, Male, 50s | Stage IV

Biomarkers: PD-L1 expression positive

Metastatic Site: right femur; brain/cerebellum

As of July 2024, Lenny described himself as NED/no evidence of disease after surgery, CyberKnife radiation, chemotherapy, and Keytruda-based immunotherapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

RET-fusion lung adenocarcinoma responding to pralsetinib and bevacizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: KIF13A-RET fusion

Metastatic Site: pleura

He had 27 months of disease-free survival on pralsetinib before pleural and nodal recurrence. After bevacizumab was added, imaging showed reduction of the pleural lesion and mediastinal nodes and circulating tumor DNA became undetectable in December 2023.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

EGFR-mutant lung adenocarcinoma in Li-Fraumeni syndrome: relapse-free after lobectomy and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Lung tumor had EGFR exon 19 deletion. Germline TP53 variant was consistent with Li-Fraumeni syndrome; prior breast cancers were HER2 positive.

As of July 2024, she was free of relapse 2 years after left inferior lobectomy and pemetrexed/cisplatin for EGFR exon 19 deletion lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated lung cancer treated with osimertinib during tuberculosis therapy

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, left axillary lymph node

Osimertinib maintained a partial response throughout 9 months of tuberculosis treatment, with no new abdominal or brain lesions. By the end of tuberculosis treatment, she was more than 7 years from her original lung-cancer diagnosis.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA lung adenocarcinoma with solitary brain metastasis: pCR after brain surgery, chemoradiation, immunotherapy, and lobectomy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 75%; negative for driver gene mutations and translocations

Metastatic Site: brain

As of May 2024, he had no recurrence after brain metastasis resection and radiation, carboplatin/pemetrexed/atezolizumab, robot-assisted right upper lobectomy with pathologic complete response, and 13 cycles of maintenance atezolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Metastatic lung adenocarcinoma presenting as a pituitary mass

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Lung adenocarcinoma with ERBB2 plus other mutations, PD-L1 TPS 1%

Metastatic Site: pituitary gland

As of May 2024, metastatic lung adenocarcinoma to the pituitary/sellar region had been diagnosed pathologically; systemic treatment, recurrence status, and longer follow-up were not described.

PubMed Central
OutcomeLiving With Cancer
Daniel, who was diagnosed with Stage II Non-Small Cell Lung CancerLung Cancer

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Survivor Story

Patient Info: Daniel West, Male | Stage II

Biomarkers: EGFR alteration

At the latest report, Daniel had no evidence of active cancer; small lung nodules were being monitored without progression while he continued osimertinib.

AACR
OutcomeCancer-Free / NED